| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 86 | 2025 | 920 | 8.480 |
Why?
|
| Troponin T | 48 | 2025 | 282 | 5.190 |
Why?
|
| Lipoprotein(a) | 17 | 2025 | 130 | 3.930 |
Why?
|
| Coronary Disease | 32 | 2024 | 676 | 3.430 |
Why?
|
| Cardiovascular Diseases | 47 | 2025 | 1959 | 3.410 |
Why?
|
| Natriuretic Peptide, Brain | 33 | 2024 | 312 | 2.990 |
Why?
|
| Biomarkers | 108 | 2025 | 3084 | 2.940 |
Why?
|
| Cholesterol, LDL | 21 | 2023 | 570 | 2.800 |
Why?
|
| Peptide Fragments | 32 | 2024 | 780 | 2.610 |
Why?
|
| C-Reactive Protein | 28 | 2025 | 428 | 2.550 |
Why?
|
| Lipoproteins | 11 | 2022 | 180 | 2.110 |
Why?
|
| Triglycerides | 16 | 2022 | 577 | 2.070 |
Why?
|
| Risk Factors | 121 | 2025 | 10282 | 2.010 |
Why?
|
| Heart Failure | 35 | 2025 | 2297 | 1.960 |
Why?
|
| Middle Aged | 180 | 2025 | 26900 | 1.770 |
Why?
|
| Atrial Fibrillation | 18 | 2024 | 659 | 1.730 |
Why?
|
| Prospective Studies | 76 | 2025 | 6141 | 1.600 |
Why?
|
| Diabetes Mellitus | 16 | 2022 | 872 | 1.590 |
Why?
|
| Risk Assessment | 52 | 2025 | 3448 | 1.560 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 13 | 2019 | 92 | 1.480 |
Why?
|
| Aged | 113 | 2025 | 19840 | 1.460 |
Why?
|
| Incidence | 65 | 2025 | 3138 | 1.440 |
Why?
|
| Stroke | 17 | 2023 | 986 | 1.350 |
Why?
|
| Inflammation | 18 | 2024 | 1442 | 1.300 |
Why?
|
| Cholesterol | 11 | 2023 | 539 | 1.250 |
Why?
|
| Male | 192 | 2025 | 61419 | 1.220 |
Why?
|
| Female | 191 | 2025 | 66678 | 1.210 |
Why?
|
| Peripheral Arterial Disease | 7 | 2021 | 289 | 1.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 24 | 2024 | 1268 | 1.100 |
Why?
|
| Brain Ischemia | 6 | 2023 | 263 | 1.090 |
Why?
|
| Lipoproteins, LDL | 6 | 2021 | 127 | 1.060 |
Why?
|
| Humans | 228 | 2025 | 124955 | 1.060 |
Why?
|
| Troponin I | 8 | 2025 | 104 | 1.050 |
Why?
|
| Lipids | 8 | 2021 | 521 | 1.010 |
Why?
|
| Lipoproteins, HDL | 6 | 2025 | 100 | 0.980 |
Why?
|
| Metabolic Syndrome | 11 | 2017 | 339 | 0.960 |
Why?
|
| Proportional Hazards Models | 28 | 2021 | 1358 | 0.910 |
Why?
|
| Coronary Artery Disease | 12 | 2024 | 800 | 0.900 |
Why?
|
| United States | 71 | 2025 | 10897 | 0.880 |
Why?
|
| Proteomics | 8 | 2025 | 501 | 0.880 |
Why?
|
| Hypertension | 10 | 2022 | 1329 | 0.870 |
Why?
|
| Weight Loss | 10 | 2015 | 483 | 0.860 |
Why?
|
| Galectin 3 | 5 | 2022 | 36 | 0.820 |
Why?
|
| Cholesterol, HDL | 12 | 2021 | 359 | 0.810 |
Why?
|
| Apolipoproteins E | 4 | 2021 | 192 | 0.800 |
Why?
|
| Obesity | 16 | 2022 | 2239 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 732 | 0.760 |
Why?
|
| Cohort Studies | 41 | 2023 | 4803 | 0.740 |
Why?
|
| Chemokine CCL2 | 7 | 2021 | 123 | 0.720 |
Why?
|
| Prediabetic State | 2 | 2018 | 57 | 0.700 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 40 | 0.690 |
Why?
|
| Blood Glucose | 16 | 2018 | 1136 | 0.690 |
Why?
|
| Lactic Acid | 7 | 2015 | 153 | 0.680 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 181 | 0.630 |
Why?
|
| Blood Pressure | 11 | 2024 | 1369 | 0.620 |
Why?
|
| Aged, 80 and over | 25 | 2025 | 6587 | 0.620 |
Why?
|
| Myocardial Infarction | 7 | 2024 | 1046 | 0.610 |
Why?
|
| Prognosis | 29 | 2023 | 4633 | 0.590 |
Why?
|
| Deoxyglucose | 4 | 2020 | 33 | 0.570 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2012 | 141 | 0.530 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 5166 | 0.530 |
Why?
|
| Alzheimer Disease | 5 | 2025 | 793 | 0.530 |
Why?
|
| Apolipoproteins B | 6 | 2019 | 134 | 0.530 |
Why?
|
| Inflammation Mediators | 5 | 2020 | 244 | 0.530 |
Why?
|
| Albuminuria | 7 | 2022 | 100 | 0.520 |
Why?
|
| Predictive Value of Tests | 19 | 2024 | 2164 | 0.510 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2020 | 19 | 0.510 |
Why?
|
| Cyclic GMP | 3 | 2021 | 95 | 0.500 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 148 | 0.490 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 55 | 0.490 |
Why?
|
| Calcinosis | 4 | 2024 | 179 | 0.480 |
Why?
|
| Time Factors | 23 | 2024 | 6328 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2017 | 2635 | 0.460 |
Why?
|
| Adiponectin | 9 | 2023 | 114 | 0.450 |
Why?
|
| Alanine Transaminase | 4 | 2023 | 157 | 0.450 |
Why?
|
| Cross-Sectional Studies | 23 | 2023 | 3416 | 0.440 |
Why?
|
| Menopause | 2 | 2022 | 77 | 0.440 |
Why?
|
| Receptors, Immunologic | 4 | 2014 | 112 | 0.430 |
Why?
|
| Hospitalization | 12 | 2021 | 1777 | 0.420 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2013 | 45 | 0.420 |
Why?
|
| Residence Characteristics | 8 | 2017 | 278 | 0.420 |
Why?
|
| Case-Control Studies | 19 | 2020 | 3296 | 0.410 |
Why?
|
| Hydroxycholesterols | 1 | 2012 | 4 | 0.410 |
Why?
|
| Aspartate Aminotransferases | 3 | 2021 | 82 | 0.400 |
Why?
|
| Vascular Calcification | 2 | 2024 | 57 | 0.400 |
Why?
|
| Genome-Wide Association Study | 15 | 2021 | 1685 | 0.400 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 398 | 0.390 |
Why?
|
| Heart Diseases | 4 | 2020 | 493 | 0.380 |
Why?
|
| Receptor for Advanced Glycation End Products | 6 | 2018 | 30 | 0.380 |
Why?
|
| Life Style | 5 | 2018 | 414 | 0.370 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 728 | 0.370 |
Why?
|
| Cystatin C | 6 | 2016 | 59 | 0.370 |
Why?
|
| Blood Proteins | 6 | 2023 | 124 | 0.370 |
Why?
|
| Diabetes Complications | 3 | 2020 | 202 | 0.360 |
Why?
|
| Phospholipases A | 3 | 2005 | 39 | 0.350 |
Why?
|
| Models, Biological | 3 | 2014 | 1461 | 0.350 |
Why?
|
| Population Surveillance | 2 | 2021 | 388 | 0.350 |
Why?
|
| Apolipoproteins | 3 | 2012 | 69 | 0.340 |
Why?
|
| Spouse Abuse | 1 | 2010 | 16 | 0.340 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2023 | 21 | 0.340 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 163 | 0.340 |
Why?
|
| Carotid Arteries | 2 | 2010 | 151 | 0.330 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 166 | 0.330 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 67 | 0.330 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2020 | 40 | 0.330 |
Why?
|
| Brain | 7 | 2025 | 2998 | 0.320 |
Why?
|
| Models, Psychological | 1 | 2010 | 138 | 0.320 |
Why?
|
| Risk | 12 | 2018 | 754 | 0.320 |
Why?
|
| Glomerular Filtration Rate | 10 | 2022 | 500 | 0.310 |
Why?
|
| Galectins | 4 | 2022 | 22 | 0.300 |
Why?
|
| Alcohol Drinking | 5 | 2023 | 343 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 553 | 0.290 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 215 | 0.280 |
Why?
|
| Body Mass Index | 13 | 2024 | 1562 | 0.280 |
Why?
|
| Testosterone | 3 | 2020 | 533 | 0.280 |
Why?
|
| Ventricular Remodeling | 3 | 2024 | 184 | 0.270 |
Why?
|
| Comorbidity | 6 | 2024 | 1531 | 0.270 |
Why?
|
| Genetic Loci | 6 | 2017 | 339 | 0.270 |
Why?
|
| Monocytes | 3 | 2019 | 353 | 0.270 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 508 | 0.270 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 2054 | 0.270 |
Why?
|
| Fructosamine | 3 | 2018 | 9 | 0.260 |
Why?
|
| gamma-Glutamyltransferase | 3 | 2014 | 47 | 0.260 |
Why?
|
| Apolipoprotein A-I | 3 | 2017 | 81 | 0.260 |
Why?
|
| Ischemia | 2 | 2020 | 361 | 0.250 |
Why?
|
| Disease Progression | 6 | 2024 | 2062 | 0.250 |
Why?
|
| Postprandial Period | 2 | 2016 | 77 | 0.250 |
Why?
|
| Ceruloplasmin | 2 | 2017 | 15 | 0.250 |
Why?
|
| White Matter | 2 | 2018 | 177 | 0.250 |
Why?
|
| Sex Factors | 10 | 2024 | 1287 | 0.240 |
Why?
|
| Prevalence | 9 | 2020 | 2448 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 235 | 0.240 |
Why?
|
| Vascular Stiffness | 3 | 2021 | 72 | 0.240 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 495 | 0.240 |
Why?
|
| Adult | 26 | 2023 | 29586 | 0.240 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2023 | 97 | 0.240 |
Why?
|
| Varicose Veins | 1 | 2024 | 29 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 93 | 0.230 |
Why?
|
| Asymptomatic Diseases | 3 | 2020 | 83 | 0.230 |
Why?
|
| beta 2-Microglobulin | 3 | 2014 | 35 | 0.230 |
Why?
|
| Lipocalins | 3 | 2014 | 30 | 0.230 |
Why?
|
| Cognition | 2 | 2019 | 731 | 0.230 |
Why?
|
| Smoking | 9 | 2018 | 1047 | 0.220 |
Why?
|
| Intramolecular Oxidoreductases | 3 | 2014 | 60 | 0.220 |
Why?
|
| Linear Models | 7 | 2017 | 682 | 0.220 |
Why?
|
| von Willebrand Factor | 2 | 2023 | 197 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2024 | 46 | 0.220 |
Why?
|
| Kidney Diseases | 2 | 2021 | 478 | 0.210 |
Why?
|
| Hyperglycemia | 2 | 2018 | 225 | 0.210 |
Why?
|
| Up-Regulation | 7 | 2020 | 867 | 0.210 |
Why?
|
| Sirolimus | 2 | 2002 | 227 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2021 | 3572 | 0.210 |
Why?
|
| Blood Specimen Collection | 2 | 2015 | 49 | 0.210 |
Why?
|
| Women's Health | 2 | 2017 | 133 | 0.210 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2017 | 137 | 0.210 |
Why?
|
| Proteome | 2 | 2021 | 243 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 4 | 2014 | 878 | 0.200 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 51 | 0.200 |
Why?
|
| Kidney | 5 | 2022 | 1365 | 0.200 |
Why?
|
| Creatinine | 5 | 2022 | 391 | 0.200 |
Why?
|
| Cognition Disorders | 2 | 2019 | 553 | 0.200 |
Why?
|
| Dementia | 2 | 2021 | 453 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2016 | 824 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 124 | 0.200 |
Why?
|
| Extracellular Matrix | 3 | 2019 | 238 | 0.200 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 12 | 0.200 |
Why?
|
| Phospholipases A2 | 4 | 2011 | 37 | 0.190 |
Why?
|
| Coronary Vessels | 2 | 2024 | 555 | 0.190 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 65 | 0.190 |
Why?
|
| Protein Precursors | 3 | 2021 | 152 | 0.180 |
Why?
|
| Stroke Volume | 4 | 2025 | 489 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 651 | 0.180 |
Why?
|
| Genotype | 8 | 2017 | 2561 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 546 | 0.180 |
Why?
|
| Interleukin-6 | 5 | 2024 | 419 | 0.180 |
Why?
|
| Arteriosclerosis | 3 | 2007 | 145 | 0.180 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 357 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2022 | 173 | 0.170 |
Why?
|
| Aortic Valve | 1 | 2024 | 443 | 0.170 |
Why?
|
| Postmenopause | 5 | 2020 | 126 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 101 | 0.170 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 8 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2020 | 107 | 0.170 |
Why?
|
| Intermittent Claudication | 1 | 2020 | 58 | 0.170 |
Why?
|
| Serum Albumin | 2 | 2018 | 110 | 0.170 |
Why?
|
| Diet, Western | 1 | 2019 | 17 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 334 | 0.170 |
Why?
|
| Myocardium | 3 | 2014 | 1019 | 0.160 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 33 | 0.160 |
Why?
|
| Age Factors | 8 | 2020 | 2819 | 0.160 |
Why?
|
| Heart Ventricles | 2 | 2021 | 769 | 0.160 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 639 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2024 | 816 | 0.160 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1327 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 38 | 0.160 |
Why?
|
| Immunoassay | 5 | 2023 | 130 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2022 | 836 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 2885 | 0.150 |
Why?
|
| Fibrosis | 3 | 2022 | 433 | 0.150 |
Why?
|
| Aging | 3 | 2023 | 1184 | 0.150 |
Why?
|
| Interleukin-18 | 2 | 2023 | 61 | 0.150 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Insulin | 6 | 2014 | 1202 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2015 | 81 | 0.140 |
Why?
|
| Adipokines | 1 | 2018 | 60 | 0.140 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2017 | 7 | 0.140 |
Why?
|
| Platelet Activation | 1 | 2017 | 71 | 0.140 |
Why?
|
| Leptin | 5 | 2018 | 214 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 347 | 0.140 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 84 | 0.130 |
Why?
|
| Logistic Models | 4 | 2016 | 1808 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2015 | 267 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2019 | 209 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2020 | 468 | 0.130 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 2905 | 0.130 |
Why?
|
| Phenotype | 5 | 2024 | 4260 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 3154 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 175 | 0.130 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 18 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2018 | 187 | 0.130 |
Why?
|
| Lysine | 2 | 2015 | 195 | 0.130 |
Why?
|
| Cardiology | 1 | 2021 | 505 | 0.130 |
Why?
|
| Caloric Restriction | 2 | 2013 | 83 | 0.130 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 30 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 109 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 2049 | 0.130 |
Why?
|
| Protein Phosphatase 1 | 1 | 2015 | 51 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 238 | 0.120 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 636 | 0.120 |
Why?
|
| Liver | 4 | 2021 | 1742 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 2018 | 163 | 0.120 |
Why?
|
| Alleles | 3 | 2015 | 1615 | 0.120 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 24 | 0.120 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2006 | 136 | 0.120 |
Why?
|
| Overweight | 2 | 2015 | 364 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2016 | 189 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 249 | 0.120 |
Why?
|
| Social Class | 1 | 2016 | 190 | 0.120 |
Why?
|
| Metformin | 2 | 2015 | 152 | 0.120 |
Why?
|
| Glycation End Products, Advanced | 4 | 2018 | 25 | 0.120 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 27 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1053 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1495 | 0.110 |
Why?
|
| Subtilisins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Echocardiography | 3 | 2024 | 1053 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 143 | 0.110 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2013 | 38 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 352 | 0.110 |
Why?
|
| Athletes | 1 | 2014 | 65 | 0.110 |
Why?
|
| Particle Size | 1 | 2014 | 124 | 0.110 |
Why?
|
| Exome | 1 | 2018 | 1033 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 561 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 31 | 0.100 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2013 | 28 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2017 | 1498 | 0.100 |
Why?
|
| Odds Ratio | 6 | 2014 | 1255 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 450 | 0.100 |
Why?
|
| Apolipoprotein B-100 | 3 | 2001 | 35 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1264 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 444 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 281 | 0.100 |
Why?
|
| Adipose Tissue | 3 | 2011 | 467 | 0.100 |
Why?
|
| Body Weight | 2 | 2014 | 991 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 59 | 0.100 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2012 | 9 | 0.100 |
Why?
|
| General Practice | 1 | 2012 | 7 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 139 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 526 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 316 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 82 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 206 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 691 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2012 | 121 | 0.090 |
Why?
|
| Organ Size | 2 | 2025 | 436 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2013 | 244 | 0.090 |
Why?
|
| Fasting | 3 | 2014 | 294 | 0.090 |
Why?
|
| Apolipoproteins A | 2 | 2001 | 47 | 0.090 |
Why?
|
| Survival Rate | 4 | 2018 | 2061 | 0.090 |
Why?
|
| tau Proteins | 2 | 2024 | 206 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 228 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 93 | 0.090 |
Why?
|
| Vasculitis | 1 | 2011 | 49 | 0.090 |
Why?
|
| Zinc | 1 | 2011 | 133 | 0.090 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 6 | 0.090 |
Why?
|
| Independent Living | 2 | 2024 | 68 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 53 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 19 | 0.090 |
Why?
|
| Temperature | 1 | 2011 | 304 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 43 | 0.090 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 68 | 0.090 |
Why?
|
| Prolactin | 1 | 2010 | 108 | 0.090 |
Why?
|
| Pulse Wave Analysis | 2 | 2021 | 46 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 73 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 76 | 0.080 |
Why?
|
| Duffy Blood-Group System | 1 | 2009 | 8 | 0.080 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2010 | 22 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 66 | 0.080 |
Why?
|
| P-Selectin | 1 | 2010 | 80 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2010 | 218 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 1437 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 435 | 0.080 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 103 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 143 | 0.080 |
Why?
|
| Mortality | 2 | 2020 | 238 | 0.080 |
Why?
|
| Proteins | 2 | 2004 | 1036 | 0.080 |
Why?
|
| Blood Platelets | 2 | 2010 | 327 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 70 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 795 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 589 | 0.080 |
Why?
|
| Angiopoietins | 1 | 2008 | 21 | 0.080 |
Why?
|
| Estrone | 1 | 2008 | 9 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1021 | 0.070 |
Why?
|
| Glycoproteins | 2 | 2024 | 370 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 25 | 0.070 |
Why?
|
| Electrocardiography | 3 | 2017 | 976 | 0.070 |
Why?
|
| Coronary Angiography | 2 | 2024 | 444 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 470 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 474 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2014 | 256 | 0.070 |
Why?
|
| Primary Prevention | 2 | 2020 | 171 | 0.070 |
Why?
|
| Iron Overload | 1 | 2007 | 16 | 0.070 |
Why?
|
| Health Promotion | 1 | 2010 | 389 | 0.070 |
Why?
|
| Cytokines | 2 | 2010 | 1294 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 816 | 0.070 |
Why?
|
| Ferritins | 1 | 2007 | 98 | 0.070 |
Why?
|
| Young Adult | 5 | 2022 | 9039 | 0.070 |
Why?
|
| HIV Infections | 2 | 2015 | 1889 | 0.060 |
Why?
|
| Community-Based Participatory Research | 2 | 2018 | 51 | 0.060 |
Why?
|
| Rosuvastatin Calcium | 2 | 2017 | 42 | 0.060 |
Why?
|
| Fibrinogen | 2 | 2017 | 155 | 0.060 |
Why?
|
| Estradiol | 1 | 2008 | 532 | 0.060 |
Why?
|
| Factor VIII | 2 | 2017 | 45 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2024 | 1024 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2024 | 1194 | 0.060 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 293 | 0.060 |
Why?
|
| Critical Illness | 2 | 2020 | 601 | 0.060 |
Why?
|
| Walking Speed | 1 | 2024 | 17 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2024 | 25 | 0.060 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2024 | 14 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 242 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2001 | 311 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 190 | 0.050 |
Why?
|
| Caveolins | 1 | 2003 | 15 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 44 | 0.050 |
Why?
|
| Calcium | 2 | 2022 | 1101 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 58 | 0.050 |
Why?
|
| Simvastatin | 2 | 2013 | 76 | 0.050 |
Why?
|
| Ezetimibe | 2 | 2013 | 95 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 626 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 63 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2024 | 156 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 199 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 136 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 569 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 869 | 0.050 |
Why?
|
| Proteinuria | 1 | 2022 | 101 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2014 | 90 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2019 | 16303 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 127 | 0.050 |
Why?
|
| Anoctamins | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 778 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 58 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1638 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 5846 | 0.050 |
Why?
|
| Energy Intake | 1 | 2004 | 493 | 0.050 |
Why?
|
| Neutrophils | 1 | 2023 | 382 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 225 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 152 | 0.040 |
Why?
|
| Mass Screening | 2 | 2018 | 783 | 0.040 |
Why?
|
| India | 1 | 2001 | 214 | 0.040 |
Why?
|
| Calibration | 2 | 2015 | 89 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2013 | 12396 | 0.040 |
Why?
|
| Educational Status | 2 | 2016 | 276 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 404 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 178 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 779 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 185 | 0.040 |
Why?
|
| Exercise | 2 | 2017 | 817 | 0.040 |
Why?
|
| Erythrocytes | 2 | 2011 | 220 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 175 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 174 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 45 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 174 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 200 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 249 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 715 | 0.040 |
Why?
|
| Memory, Episodic | 1 | 2017 | 26 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 45 | 0.040 |
Why?
|
| American Heart Association | 1 | 2020 | 322 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2018 | 127 | 0.040 |
Why?
|
| England | 1 | 2017 | 60 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 142 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1114 | 0.040 |
Why?
|
| Leg | 1 | 2018 | 158 | 0.030 |
Why?
|
| Vitamin E | 1 | 2017 | 69 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 251 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 306 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 417 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 598 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2012 | 640 | 0.030 |
Why?
|
| RNA Editing | 1 | 1996 | 34 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 184 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 72 | 0.030 |
Why?
|
| Copper | 1 | 1996 | 64 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 30 | 0.030 |
Why?
|
| Mississippi | 1 | 2016 | 33 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 59 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 50 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2008 | 90 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 879 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 692 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 134 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 236 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 221 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 38 | 0.030 |
Why?
|
| Troponin | 1 | 2016 | 76 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1507 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 925 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 22 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 269 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2018 | 340 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2015 | 90 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 138 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 375 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 18 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 35 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1549 | 0.030 |
Why?
|
| Football | 1 | 2014 | 31 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 314 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2100 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 190 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 254 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 52 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 9 | 0.030 |
Why?
|
| Diet | 2 | 2013 | 1141 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 91 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 103 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 198 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 802 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 58 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2015 | 153 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 353 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 2013 | 3 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 104 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1081 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 156 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 154 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 360 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 94 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 275 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 94 | 0.030 |
Why?
|
| Cholesterol Esters | 1 | 2012 | 15 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 231 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 194 | 0.020 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 56 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 941 | 0.020 |
Why?
|
| Complement C3 | 1 | 2012 | 48 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 142 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 724 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 726 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 685 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 171 | 0.020 |
Why?
|
| Zinc Transporter 8 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 269 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1397 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 47 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 316 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 40 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 201 | 0.020 |
Why?
|
| CD11c Antigen | 1 | 2011 | 38 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 898 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 208 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 17628 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 371 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 529 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 56 | 0.020 |
Why?
|
| Animals | 5 | 2019 | 34221 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 1752 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2010 | 107 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3057 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 96 | 0.020 |
Why?
|
| Glycolysis | 1 | 2010 | 150 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 210 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 187 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 140 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4389 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 820 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 110 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1696 | 0.020 |
Why?
|
| Premenopause | 1 | 2008 | 30 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 79 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 479 | 0.020 |
Why?
|
| Nutritional Sciences | 1 | 2008 | 76 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 89 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4530 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 285 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 25 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 44 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4391 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 19316 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 443 | 0.020 |
Why?
|
| Microspheres | 1 | 2005 | 70 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2005 | 209 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 262 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 49 | 0.010 |
Why?
|
| Sports | 1 | 2004 | 62 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 117 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 2787 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 215 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 717 | 0.010 |
Why?
|
| Aminocaproic Acid | 1 | 2001 | 4 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 2001 | 20 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 375 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 97 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2001 | 29 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 2001 | 21 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 3103 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 184 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 390 | 0.010 |
Why?
|
| Proline | 1 | 2001 | 78 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1103 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3893 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 103 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1399 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1697 | 0.010 |
Why?
|
| Arginine | 1 | 2001 | 333 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 3585 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2758 | 0.010 |
Why?
|
| Apolipoprotein B-48 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1996 | 31 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 422 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 392 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 462 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 568 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 897 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 1243 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 1561 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 3728 | 0.010 |
Why?
|